This finding was likewise reported by Oelsner et al
RELATED: Zepbound interactions to avoid When to see a doctor about Zepbound stomach pain Stomach pain is a common side effect of Zepbound, and mild discomfort shouldnt be a cause for alarm
Ohio needs to treat it like one with medication | Opinion Obesity is a significant health issue across the country
The standard practice involves starting at a low maintenance dose to assess tolerability, then gradually increasing to reach a therapeutic level that maximizes weight loss while minimizing nausea
The GLP-1 Effect: Market Penetration In the UK, 4.2 million adultsnearly 1 in 10had recently used a GLP-1 medication or expressed interest in doing so as of early 2025 Two in five overweight Britons (38%) express interest in using GLP-1s for weight loss when informed about the drugs Across Europe, the GLP-1 market is valued at 9.62 billion in 2025, with robust growth expected due to rising obesity and diabetes rates, improved access, and strong healthcare infrastructure in markets like Germany, France, and the UK Social acceptance is rising, and insurance coverage is likely to expand, further accelerating adoption
Others show optimal response at lower doses, minimizing side effects while maximizing weight loss
